Condition: HER2-positive Metastatic Breast Cancer
Intervention: Combination Product: radiation combined with pyrotinib and capecitabine
Sponsor: Jiangxi Provincial Cancer Hospital
Not yet recruiting
Feeds
6810 items (6810 unread) in 74 feeds
Acinar Cell Carcinoma
(81 unread)
Acinic Cell Carcinoma
(46 unread)
Adenoid Cystic Carcinoma
(159 unread)
Adrenal Gland Cancer
(533 unread)
Ampulla Of Vater
(68 unread)
Anal Cancer
(425 unread)
Angiosarcoma
(153 unread)
Appendix Cancer
(104 unread)
Bile Duct Cancer
(845 unread)
Brain and CNS
(878 unread)
Carcinoid
(266 unread)
Endocrine/Neuroendocrine
(808 unread)
Gall Bladder Cancer
(381 unread)
Hemangioendothelioma
(215 unread)
Hepatoblastoma
(129 unread)
Pancreas
(117 unread)
Phyllodes
(105 unread)
PMP and Mucinous Tumors
(114 unread)
Rhabdomyosarcoma
(246 unread)
Sarcoma
(1137 unread)
Trial - CNS Tumor (83 unread)
-
A Study of Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases
Posted: September 13th, 2021, 2:00pm GMT
-
Diagnosis; Objective RespOnse; THErApy
Posted: September 6th, 2021, 2:00pm GMT
Condition: Primary CNS Lymphoma
Intervention: Procedure: Lumbar puncture
Sponsors: IRCCS San Raffaele; Teresa Calimeri; Sara Steffanoni
Recruiting -
A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases
Posted: September 3rd, 2021, 2:00pm GMT
Conditions: NSCLC; EGFR Gene Mutation; EGF-R Positive Non-Small Cell Lung Cancer; Non-small Cell Lung Cancer; Brain Metastases
Intervention: Radiation: Stereotactic surgery
Sponsor: Hadassah Medical Organization
Recruiting -
Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
Posted: September 3rd, 2021, 2:00pm GMT
Condition: Leptomeningeal Metastasis
Intervention: Drug: 186RNL
Sponsor: Plus Therapeutics
Not yet recruiting -
Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas
Posted: September 1st, 2021, 2:00pm GMT
Condition: Brain Tumor
Intervention: Drug: Brivaracetam
Sponsor: University of Rochester
Not yet recruiting -
Intraoperative Laser Speckle Contrast Imaging to Assess Blood Flow During Neurosurgery
Posted: August 31st, 2021, 2:00pm GMT
Conditions: Aneurysm; AVM; Dural Arteriovenous Fistula; Glioma; Meningioma; Metastasis
Intervention: Device: Laser speckle contrast imaging (LSCI)
Sponsor: University Hospital Inselspital, Berne
Not yet recruiting -
Evaluation of the Incidence of NTRK Gene Fusion in Adult Brain Tumours
Posted: August 30th, 2021, 2:00pm GMT
Condition: Glioma
Interventions: Other: Glioma data collection; Other: Brain metastasis data collection
Sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche
Not yet recruiting -
Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases
Posted: August 30th, 2021, 2:00pm GMT
Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Melanoma; Pathologic Stage IV Cutaneous Melanoma AJCC v8
Interventions: Drug: Binimetinib; Drug: Encorafenib; Other: Questionnaire Administration
Sponsor: M.D. Anderson Cancer Center
Not yet recruiting -
Laser Interstitial Thermal Ablation and Stereotactic Radiosurgery for Patients With Spine Metastases
Posted: August 27th, 2021, 2:00pm GMT
Conditions: Neoplasm Metastasis; Spinal Cord Diseases; Spinal Cord Compression; Spinal Cord Tumor; Spine Metastases
Interventions: Procedure: Stereotactic Laser Ablation; Radiation: Stereotactic Radiosurgery; Diagnostic Test: MRI guided laser ablation
Sponsors: Henry Ford Health System; Medtronic
Recruiting -
A Study to Measure the Effect of Brain Stimulation on Hand Strength and Function in Patients With Brain Tumors
Posted: August 26th, 2021, 2:00pm GMT
Conditions: Brain Tumor; Brain Cancer; Motor Cortex; Lesion
Intervention: Procedure: Intraoperative Brain Simulation - Alternate Stimulation Parameters
Sponsor: Medical College of Wisconsin
Not yet recruiting -
NEO100 and High-Grade Meningioma
Posted: August 26th, 2021, 2:00pm GMT
Condition: Residual, Progressive or Recurrent Grade II or III Meningioma
Intervention: Drug: NEO100
Sponsor: Neonc Technologies, Inc.
Not yet recruiting -
Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma
Posted: August 26th, 2021, 2:00pm GMT
Conditions: Refractory and Relapsed Primary CNS Lymphoma; PCNSL; Non Hodgkin Lymphoma
Interventions: Drug: Orelabrutinib; Drug: Thiotepa
Sponsors: Huiqiang Huang; Guangdong 999 Brain Hospital
Not yet recruiting -
Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS
Posted: August 26th, 2021, 2:00pm GMT
Conditions: Diffuse Large B-Cell Lymphoma; Drug Toxicity
Intervention: Drug: Glucarpidase 1000 UNT [Voraxaze]
Sponsors: Fundacion CRIS de Investigación para Vencer el Cáncer; BioClever 2005 S.L.; Eurofins ADME, S.L.; NTShub, S.L.; BTG International Inc.
Recruiting -
ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases
Posted: August 24th, 2021, 2:00pm GMT
Condition: HER2-positive, Metastatic Breast Cancer
Intervention: Drug: ARX788
Sponsor: Fudan University
Recruiting -
The Neural Coding of Speech Across Human Languages
Posted: August 20th, 2021, 2:00pm GMT
Conditions: Epilepsy; Brain Tumor; Speech; Bilingualism
Intervention: Behavioral: Speech Tasks
Sponsors: University of California, San Francisco; University of California, Berkeley; Lawrence Livermore National Laboratory; The University of Hong Kong; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting -
Study of Nivolumab and Ipilimumab Plus Chemotherapy as a Treatment for Patients With Stage IV Lung Cancer With Brain Metastases
Posted: August 19th, 2021, 2:00pm GMT
Conditions: Non Small Cell Lung Cancer; Brain Metastases, Adult; Lung Cancer
Interventions: Drug: Ipilimumab; Drug: Nivolumab; Drug: Carboplatin; Drug: Cisplatin; Drug: Paclitaxel; Drug: Pemetrexed
Sponsor: Fundación GECP
Not yet recruiting -
NTS-WBRT VS HA-WBRT in Brain Metastases
Posted: August 19th, 2021, 2:00pm GMT
Condition: Brain Metastases
Interventions: Radiation: NTS-WBRT (normal tissue sparing whole brain radiation therapy); Radiation: HA-WBRT (hippocampal avoidance whole brain radiation therapy); Drug: Memantine
Sponsor: Massachusetts General Hospital
Not yet recruiting -
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Posted: August 13th, 2021, 2:00pm GMT
Conditions: Advanced Cancer; Metastatic Solid Tumor
Interventions: Drug: Repotrectinib; Drug: Irinotecan and temozolomide
Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting -
Effect of Dexmedetomidine on Quality of Recovery in Non-functioning Pituitary Adenoma Patients Undergoing Endoscopic Transsphenoidal Surgery
Posted: August 13th, 2021, 2:00pm GMT
Condition: Non-functioning Pituitary Adenoma
Interventions: Drug: Dexmedetomidine; Drug: normal saline
Sponsor: Seoul National University Hospital
Not yet recruiting -
Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide
Posted: August 9th, 2021, 2:00pm GMT
Condition: Meningioma
Interventions: Drug: 177Lu-DOTA-JR11 (Phase 0); Cycle 1 and Cycle 2 (cross-over); Drug: 177Lu-DOTATOC (Phase 0); Cycle 1 and Cycle 2 (cross-over), Cycle 3 and 4; Drug: 177Lu-DOTA-JR11 (Phase I/II)
Sponsors: University Hospital, Basel, Switzerland; Swiss Cancer League
Recruiting -
Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma and Choroid Plexus Carcinoma Prior to Second-Look Surgery
Posted: August 6th, 2021, 2:00pm GMT
Conditions: Atypical Choroid Plexus Papilloma; Choroid Plexus Carcinoma
Interventions: Drug: Melphalan; Drug: Carboplatin; Drug: Topotecan
Sponsors: Weill Medical College of Cornell University; Columbia University
Not yet recruiting -
Niraparib in Tumors Metastatic to the CNS
Posted: August 5th, 2021, 2:00pm GMT
Conditions: Metastatic Cancer; Central Nervous System Cancer
Intervention: Drug: Niraparib
Sponsors: Massachusetts General Hospital; GlaxoSmithKline
Not yet recruiting -
Patient Perceptions Around Quality of Care Through Telemedicine in Neuro-Oncology
Posted: August 3rd, 2021, 2:00pm GMT
Conditions: Central Nervous System Neoplasm; Leptomeningeal Neoplasm; Metastatic Malignant Neoplasm in the Brain; Primary Brain Neoplasm
Interventions: Other: Electronic Health Record Review; Other: Survey Administration
Sponsor: M.D. Anderson Cancer Center
Recruiting -
Intrathecal Chemotherapy for Central Nervous System Metastasis in Retinoblastoma
Posted: May 26th, 2021, 2:00pm GMT
Condition: Retinoblastoma, Extraocular
Intervention: Drug: Melphalan
Sponsors: Eye & ENT Hospital of Fudan University; Zhongshan Ophthalmic Center, Sun Yat-sen University; Children's Hospital of Fudan University
Recruiting -
Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery
Posted: April 28th, 2021, 2:00pm GMT
Conditions: Pituitary Tumor; Blood Loss; Surgery
Interventions: Drug: Tranexamic acid; Drug: Placebo
Sponsor: University of North Carolina, Chapel Hill
Recruiting -
A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)
Posted: March 3rd, 2021, 3:00pm GMT
Conditions: NSCLC; Brain Metastases; Leptomeningeal Metastasis
Interventions: Drug: almonertinib; Drug: LM-first line treatment; Drug: LM-second line treatment
Sponsor: Henan Cancer Hospital
Recruiting -
A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)
Posted: February 21st, 2021, 3:00pm GMT
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin; Drug: Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin
Sponsors: AstraZeneca; Parexel
Not yet recruiting -
A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer
Posted: February 5th, 2021, 3:00pm GMT
Condition: Breast Cancer
Intervention: Drug: Trastuzumab Deruxtecan
Sponsors: AstraZeneca; Daiichi Sankyo, Inc.
Recruiting -
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
Posted: November 25th, 2020, 3:00pm GMT
Conditions: Neoplasms; Colorectal Neoplasms; Melanoma; Pancreatic Neoplasms; Sarcoma; Ovarian Neoplasms; Brain Neoplasms; Thyroid Neoplasms; Neuroendocrine Tumors; Cholangiocarcinoma; Salivary Gland Neoplasms; Head and Neck Neoplasms; Thyroid Cancer, Papillary; Lymphoma, Large-Cell, Anaplastic; Neoplasms by Site; Respiratory Tract Neoplasms; Thoracic Neoplasms; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Central Nervous System
Intervention: Drug: Alectinib
Sponsor: Hoffmann-La Roche
Recruiting -
A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response
Posted: November 17th, 2020, 3:00pm GMT
Condition: Advanced Unresectable or Metastatic Solid Malignancy
Interventions: Drug: Entrectinib; Drug: Inavolisib; Drug: Alectinib; Drug: Ipatasertib; Drug: Atezolizumab; Drug: Trastuzumab Emtansine; Drug: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf; Drug: Tucatinib; Drug: Investigator's Choice of Chemotherapy; Drug: Paclitaxel; Drug: Tiragolumab; Drug: Pralsetinib
Sponsor: Genentech, Inc.
Recruiting -
Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
Posted: October 30th, 2020, 2:00pm GMT
Conditions: Central Nervous System Lymphoma; Diffuse Large B-Cell Lymphoma
Interventions: Drug: Lenalidomide; Drug: Methotrexate; Biological: Nivolumab; Biological: Rituximab
Sponsor: National Cancer Institute (NCI)
Recruiting -
Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases
Posted: October 30th, 2020, 2:00pm GMT
Conditions: Small-cell Lung Cancer; Brain Metastases
Interventions: Drug: Carboplatin; Drug: Etoposide; Drug: Atezolizumab
Sponsors: Jeffrey Clarke; Genentech, Inc.; Duke University
Recruiting -
Corticotrophin-releasing Hormone (CRH) Stimulation for 18F-FDG-PET Detection of Pituitary Adenoma in Cushing s Disease
Posted: September 30th, 2020, 2:00pm GMT
Conditions: Cushing's Disease; Pituitary Adenoma
Intervention: Drug: Acthrel
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Not yet recruiting -
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 Mutations
Posted: August 20th, 2020, 2:00pm GMT
Conditions: Cholangiocarcinoma; Chondrosarcoma; Glioma; Any Solid Tumor
Intervention: Drug: LY3410738
Sponsors: Eli Lilly and Company; Loxo Oncology, Inc.
Recruiting -
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
Posted: June 1st, 2020, 2:00pm GMT
Condition: Metastatic Non-small Cell Lung Cancer
Interventions: Drug: Osimertinib; Drug: Carboplatin; Drug: Pemetrexed
Sponsors: Memorial Sloan Kettering Cancer Center; AstraZeneca; GUARDANT HEALTH
Recruiting -
Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases
Posted: June 1st, 2020, 2:00pm GMT
Condition: Brain Metastases
Intervention: Drug: 18F fluciclovine
Sponsors: Blue Earth Diagnostics; Precision For Medicine
Recruiting -
Study to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metastases (PURSUE)
Posted: June 1st, 2020, 2:00pm GMT
Condition: Brain Metastases
Intervention: Drug: 18F fluciclovine
Sponsors: Blue Earth Diagnostics; Precision For Medicine
Recruiting -
Safety Study of Pritumumab in Brain Cancer
Posted: May 21st, 2020, 2:00pm GMT
Conditions: Malignant Primary Brain Tumors; Brain Metastases, Adult
Intervention: Biological: Pritumumab
Sponsors: Nascent Biotech; Hoag Memorial Hospital Presbyterian
Recruiting -
Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease
Posted: April 9th, 2020, 2:00pm GMT
Condition: Cushing's Disease
Intervention: Drug: Vorinostat
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Not yet recruiting -
177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors
Posted: March 19th, 2020, 2:00pm GMT
Conditions: Leptomeningeal Metastasis; Solid Tumor, Adult
Intervention: Biological: radiolabeled DPTA-omburtamab
Sponsor: Y-mAbs Therapeutics
Recruiting -
Camrelizumab Combined With Local Treatment in NSCLC Patients With BM
Posted: March 2nd, 2020, 3:00pm GMT
Conditions: NSCLC Stage IV; Brain Metastases; Immunotherapy
Interventions: Drug: Immunotherapy; Radiation: WBRT; Drug: Chemotherapy
Sponsor: Zhejiang Cancer Hospital
Recruiting -
HA-WBRT vs SRS in Patients With Multiple Brain Metastases
Posted: February 20th, 2020, 3:00pm GMT
Condition: Brain Metastases
Interventions: Radiation: Hippocampal Avoiding Whole Brain Radiation Therapy with Simultaneous Integrated Boost; Radiation: Single session or hypofractionated stereotactic radiosurgery
Sponsor: Medical University Innsbruck
Recruiting -
Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer
Posted: January 31st, 2020, 3:00pm GMT
Conditions: Leptomeningeal Neoplasm; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Malignant Neoplasm in the Brain; Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
Interventions: Drug: Sapanisertib; Drug: Telaglenastat Hydrochloride
Sponsor: National Cancer Institute (NCI)
Recruiting -
Detection of PitNET Tissue During TSS Using Bevacizumab-800CW
Posted: December 30th, 2019, 3:00pm GMT
Conditions: Pituitary Tumor; Pituitary Adenoma; Pituitary Macroadenoma
Interventions: Drug: Bevacizumab-IRDye800CW; Device: Molecular Fluorescence Endoscopy platform
Sponsor: University Medical Center Groningen
Recruiting -
Fluoroethyltyrosine in Detecting Tumors in Participants With Recurrent Intracranial Tumors
Posted: August 5th, 2019, 2:00pm GMT
Conditions: Intracranial Neoplasm; Low Grade Glioma; Recurrent Glioblastoma; Recurrent World Health Organization (WHO) Grade II Glioma; Recurrent WHO Grade III Glioma
Interventions: Drug: F-18 Fluoroethyltyrosine (FET); Procedure: Positron Emission Tomography (PET)
Sponsor: Thomas Hope
Recruiting -
Epidemiology of Pituitary Tumours: Prevalence of Associated Neoplasia
Posted: June 4th, 2019, 2:00pm GMT
Conditions: Pituitary Tumor; Endocrine Neoplasia; Hyperparathyroidism; Solid Tumor; Familial Tumor Syndrome
Intervention: Other: Registration of familial forms and associated neoplasia
Sponsor: Neuromed IRCCS
Recruiting -
AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery
Posted: May 29th, 2019, 2:00pm GMT
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: BGB 324 (before surgery); Drug: BGB 324 (after surgery)
Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; National Cancer Institute (NCI); BerGenBio ASA
Recruiting -
Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)
Posted: May 28th, 2019, 2:00pm GMT
Conditions: Central Nervous System Lymphoma; Secondary Central Nervous System Lymphoma
Interventions: Drug: TEDD-R; Drug: TEDDI-R; Drug: Ibrutinib; Drug: Cytarabine; Drug: Isavuconazole; Drug: Methotrexate
Sponsor: National Cancer Institute (NCI)
Recruiting -
Effect of Electroacupuncture on Opioid-induced Constipation in Patients With Cancer
Posted: January 9th, 2019, 3:00pm GMT
Condition: Opioid-induced Constipation in Patients With Cancer
Interventions: Other: Electroacupuncture group; Other: Sham electroacupuncture group
Sponsor: Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Recruiting -
Pre-Operative or Post-Operative Stereotactic Radiosurgery in Treating Patients With Operative Metastatic Brain Tumors
Posted: November 21st, 2018, 3:00pm GMT
Conditions: Malignant Solid Neoplasm; Metastatic Malignant Neoplasm in the Brain
Interventions: Procedure: Conventional Surgery; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Radiation: Stereotactic Radiosurgery
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting -
Nasal Packing Following Endoscopic Endonasal Pituitary Resection
Posted: September 19th, 2018, 2:00pm GMT
Condition: Pituitary Tumor
Interventions: Procedure: No nasal packing.; Procedure: Nasal Packing
Sponsors: Ottawa Hospital Research Institute; The Physicians' Services Incorporated Foundation
Recruiting -
ANG1005 in Leptomeningeal Disease From Breast Cancer
Posted: August 3rd, 2018, 2:00pm GMT
Conditions: Leptomeningeal Carcinomatosis; Leptomeningeal Metastases; Brain Metastases; HER2-negative Breast Cancer
Interventions: Drug: ANG1005; Drug: Physician's Best Choice
Sponsor: Angiochem Inc
Not yet recruiting -
Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors
Posted: July 26th, 2018, 2:00pm GMT
Conditions: Recurrent Diffuse Intrinsic Pontine Glioma; Recurrent Malignant Glioma; Recurrent Medulloblastoma; Recurrent Primary Central Nervous System Neoplasm; Refractory Diffuse Intrinsic Pontine Glioma; Refractory Malignant Glioma; Refractory Medulloblastoma; Refractory Primary Central Nervous System Neoplasm
Intervention: Drug: Savolitinib
Sponsor: National Cancer Institute (NCI)
Recruiting -
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5-15 Brain Metastases
Posted: June 8th, 2018, 2:00pm GMT
Condition: Brain Metastases
Interventions: Drug: Memantine; Radiation: Hippocampal-avoidant (HA-WBRT) Radiotherapy; Procedure: Stereotactic Radiosurgery (SRS)
Sponsors: Canadian Cancer Trials Group; Alliance for Clinical Trials in Oncology; NRG Oncology
Recruiting -
[18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers
Posted: May 29th, 2018, 2:00pm GMT
Conditions: Healthy Subject; Intracranial Neoplasm; Glioblastoma
Interventions: Drug: Fluorine F 18 DASA-23; Procedure: Positron Emission Tomography
Sponsor: Guido A. Davidzon, MD, SM
Recruiting -
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Posted: February 6th, 2018, 3:00pm GMT
Conditions: Recurrent Glioblastoma Multiforme; Primary Glioblastoma Multiforme; Brain Neoplasms, Malignant; Leptomeningeal Disease (LMD)
Interventions: Radiation: Radiation Therapy; Drug: AZD1390
Sponsor: AstraZeneca
Recruiting -
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Posted: July 28th, 2017, 2:00pm GMT
Conditions: Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma; Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma; Low Grade Glioma; Malignant Glioma; Recurrent Childhood Central Nervous System Neoplasm; Recurrent Childhood Ependymoma; Recurrent Childhood Malignant Germ Cell Tumor; Recurrent Childhood Non-Hodgkin Lymphoma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Soft Tissue Sarcoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Osteosarcoma; Refractory Childhood Malignant Germ Cell Tumor; Refractory Ependymoma; Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Refractory Glioma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Glioma; Refractory Malignant Solid Neoplasm; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Primary Central Nervous System Neoplasm; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma; Rhabdoid Tumor; Wilms Tumor
Intervention: Drug: Olaparib
Sponsor: National Cancer Institute (NCI)
Recruiting -
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Posted: July 18th, 2017, 2:00pm GMT
Conditions: Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma; Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma; Ependymoma; Ewing Sarcoma; Hepatoblastoma; Langerhans Cell Histiocytosis; Malignant Germ Cell Tumor; Malignant Glioma; Osteosarcoma; Peripheral Primitive Neuroectodermal Tumor; Recurrent Childhood Central Nervous System Neoplasm; Recurrent Childhood Non-Hodgkin Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Neuroblastoma; Refractory Malignant Solid Neoplasm; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Primary Central Nervous System Neoplasm; Rhabdoid Tumor; Rhabdomyosarcoma; Soft Tissue Sarcoma; Wilms Tumor
Interventions: Other: Laboratory Biomarker Analysis; Drug: Vemurafenib
Sponsor: National Cancer Institute (NCI)
Recruiting -
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Posted: July 11th, 2017, 2:00pm GMT
Conditions: Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Malignant Glioma; Recurrent Ependymoma; Recurrent Ewing Sarcoma; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Primary Central Nervous System Neoplasm; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Germ Cell Tumor; Refractory Malignant Solid Neoplasm; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Primary Central Nervous System Neoplasm; Rhabdoid Tumor; Stage III Osteosarcoma AJCC v7; Stage III Soft Tissue Sarcoma AJCC v7; Stage IV Osteosarcoma AJCC v7; Stage IV Soft Tissue Sarcoma AJCC v7; Stage IVA Osteosarcoma AJCC v7; Stage IVB Osteosarcoma AJCC v7; Wilms Tumor
Interventions: Other: Laboratory Biomarker Analysis; Other: Pharmacological Study; Drug: Samotolisib
Sponsor: National Cancer Institute (NCI)
Recruiting -
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
Posted: July 11th, 2017, 2:00pm GMT
Conditions: Advanced Malignant Solid Neoplasm; Recurrent Ependymoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Glioma; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Rhabdoid Tumor; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Refractory Ependymoma; Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Refractory Glioma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Germ Cell Tumor; Refractory Malignant Glioma; Refractory Malignant Solid Neoplasm; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Primary Central Nervous System Neoplasm; Refractory Rhabdoid Tumor; Refractory Rhabdomyosarcoma; Wilms Tumor
Interventions: Drug: Larotrectinib; Drug: Larotrectinib Sulfate
Sponsor: National Cancer Institute (NCI)
Recruiting -
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
Posted: July 11th, 2017, 2:00pm GMT
Conditions: Glioblastoma Multiforme (GBM); Glioblastoma; Glioma of Brain; Glioblastoma, Adult; Brain Tumor; Brain Tumor, Primary; Brain Tumor Adult; Cancer; Brain Cancer
Interventions: Drug: Capecitabine; Drug: Temozolomide
Sponsor: Northwell Health
Recruiting -
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Posted: July 7th, 2017, 2:00pm GMT
Conditions: Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma; Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma; Low Grade Glioma; Malignant Glioma; Recurrent Childhood Ependymoma; Recurrent Childhood Malignant Germ Cell Tumor; Recurrent Childhood Medulloblastoma; Recurrent Childhood Non-Hodgkin Lymphoma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Soft Tissue Sarcoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Solid Neoplasm; Recurrent Neuroblastoma; Recurrent Osteosarcoma; Recurrent Primary Central Nervous System Neoplasm; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Solid Neoplasm; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Primary Central Nervous System Neoplasm; Rhabdoid Tumor; Stage III Soft Tissue Sarcoma AJCC v7; Stage IV Soft Tissue Sarcoma AJCC v7; Wilms Tumor
Interventions: Drug: Erdafitinib; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study
Sponsor: National Cancer Institute (NCI)
Recruiting -
Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers
Posted: June 2nd, 2017, 2:00pm GMT
Conditions: Medulloblastoma; Ependymoma; Pineal RegionTumors; Choroid Plexus Tumors; Atypical/Malignant Meningioma
Intervention: Drug: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting -
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Posted: May 16th, 2017, 2:00pm GMT
Conditions: Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Histiocytic Sarcoma; Juvenile Xanthogranuloma; Langerhans Cell Histiocytosis; Malignant Glioma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Ependymoma; Recurrent Ewing Sarcoma; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Primary Central Nervous System Neoplasm; Recurrent Rhabdoid Tumor; Recurrent Soft Tissue Sarcoma; Refractory Ewing Sarcoma; Refractory Glioma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Germ Cell Tumor; Refractory Malignant Solid Neoplasm; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Peripheral Primitive Neuroectodermal Tumor; Refractory Primary Central Nervous System Neoplasm; Refractory Rhabdoid Tumor; Refractory Rhabdomyosarcoma; Rhabdoid Tumor; Stage III Osteosarcoma AJCC v7; Stage III Soft Tissue Sarcoma AJCC v7; Stage IV Osteosarcoma AJCC v7; Stage IV Soft Tissue Sarcoma AJCC v7; Stage IVA Osteosarcoma AJCC v7; Stage IVB Osteosarcoma AJCC v7; Wilms Tumor
Interventions: Procedure: Biopsy; Procedure: Biospecimen Collection; Drug: Ensartinib; Drug: Erdafitinib; Other: Laboratory Biomarker Analysis; Drug: Larotrectinib; Procedure: Mutation Carrier Screening; Drug: Olaparib; Drug: Palbociclib; Other: Pharmacological Study; Drug: Samotolisib; Drug: Selpercatinib; Drug: Selumetinib Sulfate; Drug: Tazemetostat; Drug: Tipifarnib; Drug: Ulixertinib; Drug: Vemurafenib
Sponsor: National Cancer Institute (NCI)
Recruiting -
Social Emotional Development in Young Children With Cancer
Posted: March 22nd, 2017, 2:00pm GMT
Conditions: Solid Tumor, Childhood; Brain Tumor, Pediatric
Intervention: Behavioral: Questionnaires
Sponsors: St. Jude Children's Research Hospital; American Cancer Society, Inc.
Recruiting -
Pembrolizumab In Central Nervous System Metastases
Posted: September 1st, 2016, 2:00pm GMT
Condition: Brain Metastases
Interventions: Drug: Pembrolizumab; Radiation: MRI; Radiation: PET/CT; Procedure: Stereotactic Radiosurgery
Sponsors: Massachusetts General Hospital; Merck Sharp & Dohme Corp.
Recruiting -
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
Posted: June 15th, 2016, 2:00pm GMT
Conditions: Glioblastoma; Anaplastic Astrocytoma; Anaplastic Oligoastrocytoma; Glioma; Brain Neoplasm; Brain Cancer; Brain Tumor; Brain Tumor, Recurrent; Brain Neoplasm, Malignant
Interventions: Drug: Intra-arterial Cetuximab; Drug: Intra-arterial Mannitol; Radiation: Hypofractionated re-irradiation
Sponsor: Northwell Health
Recruiting -
Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer
Posted: February 12th, 2016, 3:00pm GMT
Conditions: Melanoma; Non-small Cell Lung Cancer; Brain Metastasis
Intervention: Drug: Pembrolizumab plus Bevacizumab
Sponsor: Yale University
Recruiting -
A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children
Posted: December 22nd, 2015, 3:00pm GMT
Condition: Solid Tumors Harboring NTRK Fusion
Intervention: Drug: Larotrectinib (Vitrakvi, BAY2757556)
Sponsor: Bayer
Recruiting -
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Posted: October 5th, 2015, 2:00pm GMT
Conditions: Breast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell, Anaplastic; Melanoma; Neuroendocrine Tumors; Non-Small Cell Lung Cancer; Ovarian Cancer; Pancreatic Cancer; Papillary Thyroid Cancer; Primary Brain Tumors; Renal Cell Carcinoma; Sarcomas; Salivary Gland Cancers; Adult Solid Tumor
Intervention: Drug: Entrectinib
Sponsor: Hoffmann-La Roche
Recruiting -
T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors
Posted: May 13th, 2015, 2:00pm GMT
Conditions: Brain Tumor, Recurrent; Brain Tumor, Refractory
Intervention: Biological: HER2-specific T cells
Sponsors: Baylor College of Medicine; Center for Cell and Gene Therapy, Baylor College of Medicine; Houston Methodist Hospital, TX
Recruiting -
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
Posted: March 19th, 2015, 2:00pm GMT
Conditions: Non-Hodgkin Lymphoma; Burkitt Lymphoma; Diffuse Large B-Cell Lymphoma; Primary Mediastinal B-cell Lymphoma; CD20+ Lymphoblastic Lymphoma; Follicular Lymphoma, Grade III
Interventions: Drug: Obinutuzumab; Drug: Liposomal ARA-C; Drug: Ifosfamide; Drug: Carboplatin; Drug: Etoposide
Sponsors: New York Medical College; Roswell Park Cancer Institute
Recruiting -
Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System
Posted: March 18th, 2015, 2:00pm GMT
Conditions: Metastatic Brain Tumor; Primary Brain Tumor; Epileptic/Seizure Foci; Movement Disorders
Intervention: Device: NeuroBlate System
Sponsor: Monteris Medical
Recruiting -
Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas
Posted: November 13th, 2014, 3:00pm GMT
Conditions: Pituitary Neoplasms; Adenoma
Intervention: Drug: cabergoline
Sponsors: St. Olavs Hospital; Norwegian University of Science and Technology
Recruiting -
Trial Evaluating an Enhanced Physical Activity Intervention to Improve Cognitive Late Effects in Children Treated With Cranial Radiation for Brain Tumors
Posted: June 3rd, 2014, 2:00pm GMT
Condition: Brain Tumor
Intervention: Behavioral: Physical Activity
Sponsor: National Cancer Institute (NCI)
Recruiting -
Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors
Posted: April 15th, 2014, 2:00pm GMT
Conditions: Malignant Rhabdoid Tumor; Atypical Teratoid Rhabdoid Tumor
Interventions: Drug: alisertib; Drug: methotrexate; Drug: cisplatin; Drug: carboplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: topotecan; Drug: vincristine; Procedure: Surgical resection; Radiation: Radiation therapy
Sponsors: St. Jude Children's Research Hospital; Millennium Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc.
Recruiting -
Evaluation of the SickKids Team Obesity Management Program
Posted: January 24th, 2012, 3:00pm GMT
Condition: Obesity
Intervention: Behavioral: STOMP Clinic
Sponsor: The Hospital for Sick Children
Recruiting -
Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological Studies
Posted: April 23rd, 2010, 2:00pm GMT
Conditions: Sarcoma; Endocrine Tumors; Neuroblastoma; Retinoblastoma; Renal Cancer
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting -
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
Posted: April 23rd, 2009, 2:00pm GMT
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: concomitant temozolomide (TMZ); Radiation: radiotherapy; Drug: procarbazine; Drug: adjuvant temozolomide (TMZ); Drug: CCNU; Drug: vincristine
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); European Organisation for Research and Treatment Center (EORTC); Canadian Cancer Trials Group
Recruiting -
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
Posted: March 27th, 2009, 2:00pm GMT
Conditions: Brain Cancer; Glioma
Intervention: Procedure: MRI and advanced MRI sequences
Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting -
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
Posted: August 18th, 2008, 2:00pm GMT
Conditions: Acute Lymphoblastic Leukemia; Brain Neoplasm; Hematopoietic Cell Transplantation Recipient; Hodgkin Lymphoma; Osteosarcoma; Rhabdomyosarcoma
Interventions: Procedure: Assessment of Therapy Complications; Other: Questionnaire Administration
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting -
Study of Skin Tumors in Tuberous Sclerosis
Posted: January 21st, 2000, 3:00pm GMT
Condition: Tuberous Sclerosis
Intervention:
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); Uniformed Services University of the Health Sciences
Recruiting -
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
Posted: November 4th, 1999, 3:00pm GMT
Conditions: Panhypopituitarism; Gigantism/Acromegaly; Prolactinoma; Cushing Disease
Intervention:
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting